Literature DB >> 2341306

DNA typing for class II HLA antigens with allele-specific or group-specific amplification. II. Typing for alleles of the DRw52-associated group.

M Fernandez-Vina1, W Shumway, P Stastny.   

Abstract

Codons 9-12 of the first domain of DRB1, which encode the amino acid sequence EYST (in single-letter code), served as the basis for the construction of a polymerase chain reaction primer specific for DRB1 of the whole DRw52 group. Using this primer for the 5' end and a primer for a conserved region at the 3' end, we could amplify selectively the DRB1 genes of DRw17-, w18-, w11-, w13-, w14, and w8-positive haplotypes. DRB3 genes of DR3,DR5 and DRw6 were also specifically amplified, separately. This selectively amplified DNA could then be used in a blotting procedure for hybridization with oligonucleotide probes chosen to define the polymorphisms that characterize these alleles and their subsets. Patterns of hybridization for groups of related specificities have been described, and their frequencies were determined in representative panels available in our laboratory. The results presented illustrate the extraordinary power of this new DNA typing procedure. Using these relatively simple methods it is possible to define, with certainty, allelic forms of DRB1 and DRB3 associated with the DRw52 group. The ability to type extends far beyond the capabilities of present serology; the precision achieved with this method in panel typings is unprecedented.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2341306     DOI: 10.1016/0198-8859(90)90102-u

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  8 in total

1.  Extensive genetic diversity in the HLA class II region of Africans, with a focally predominant allele, DRB1*1304.

Authors:  A V Hill; C E Allsopp; D Kwiatkowski; T E Taylor; S N Yates; N M Anstey; J J Wirima; D R Brewster; A J McMichael; M E Molyneux
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

2.  HLA-DRB3 gene alleles in Caucasian patients with Graves' disease.

Authors:  B O Boehm; P Kühnl; B J Manfras; M Chen; J C Lee; G Holzberger; S Seidl; E Schifferdecker; P M Schumm-Draeger; K H Usadel
Journal:  Clin Investig       Date:  1992-10

3.  HLA class II genes in primary sclerosing cholangitis and chronic inflammatory bowel disease: no HLA-DRw52a association in Swedish patients with sclerosing cholangitis.

Authors:  H Zetterquist; U Broomé; K Einarsson; O Olerup
Journal:  Gut       Date:  1992-07       Impact factor: 23.059

4.  HLA antigens and risk for development of pemphigus foliaceus (fogo selvagem) in endemic areas of Brazil.

Authors:  J R Moraes; M E Moraes; M Fernandez-Vina; L A Diaz; H Friedman; I T Campbell; R R Alvarez; S A Sampaio; E A Rivitti; P Stastny
Journal:  Immunogenetics       Date:  1991       Impact factor: 2.846

5.  HLA-DR typing using DNA amplification by the polymerase chain reaction and sequential hybridization to sequence-specific oligonucleotide probes.

Authors:  B P Wordsworth; C E Allsopp; R P Young; J I Bell
Journal:  Immunogenetics       Date:  1990       Impact factor: 2.846

6.  Alleles at four HLA class II loci determined by oligonucleotide hybridization and their associations in five ethnic groups.

Authors:  M A Fernandez-Viña; X J Gao; M E Moraes; J R Moraes; I Salatiel; S Miller; J Tsai; Y P Sun; J B An; Z Layrisse
Journal:  Immunogenetics       Date:  1991       Impact factor: 2.846

7.  Certain HLA-DR5 and -DR6 major histocompatibility complex class II alleles are associated with a CD8 lymphocytic host response to human immunodeficiency virus type 1 characterized by low lymphocyte viral strain heterogeneity and slow disease progression.

Authors:  S Itescu; S Rose; E Dwyer; R Winchester
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-22       Impact factor: 11.205

8.  Association of amino acid sequences in the HLA-DQB1 first domain with antitopoisomerase I autoantibody response in scleroderma (progressive systemic sclerosis).

Authors:  J D Reveille; E Durban; M J MacLeod-St Clair; R Goldstein; R Moreda; R D Altman; F C Arnett
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.